David Calhoun to Aged
This is a "connection" page, showing publications David Calhoun has written about Aged.
Connection Strength
2.174
-
Siddiqui M, Judd EK, Zhang B, Dudenbostel T, Carey RM, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. Hypertension. 2021 02; 77(2):435-444.
Score: 0.087
-
Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension. 2019 09; 74(3):652-659.
Score: 0.079
-
Siddiqui M, Judd EK, Jaeger BC, Bhatt H, Dudenbostel T, Zhang B, Edwards LJ, Oparil S, Calhoun DA. Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension. Hypertension. 2019 01; 73(1):132-141.
Score: 0.076
-
Siddiqui M, Phillips RA, Bursztyn M, Sica D, Velasco A, Judd EK, Dudenbostel T, Lloyd SG, Oparil S, Calhoun DA. Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. Hypertension. 2018 07; 72(1):3-9.
Score: 0.073
-
Cai A, Calhoun DA. Antihypertensive Medications and Falls in the Elderly. Am J Hypertens. 2018 02 09; 31(3):281-283.
Score: 0.071
-
Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
Score: 0.068
-
Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 2016 10; 68(4):995-1003.
Score: 0.064
-
Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016 06; 10(6):493-9.
Score: 0.063
-
Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
Score: 0.059
-
Breaux-Shropshire TL, Whitt L, Griffin RL, Shropshire AT, Calhoun DA. Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf. 2014 Jul; 62(7):292-300.
Score: 0.056
-
Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
Score: 0.054
-
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
Score: 0.053
-
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
Score: 0.052
-
Calhoun DA, Lacourci?re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
Score: 0.052
-
Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M?nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
Score: 0.046
-
Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
Score: 0.045
-
Lacourci?re Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011 Oct; 25(10):615-22.
Score: 0.044
-
Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010 Aug 15; 6(4):363-8.
Score: 0.042
-
Czarina Acelajado M, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol. 2009 Dec; 57(6):787-812.
Score: 0.040
-
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
Score: 0.039
-
Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008 Aug; 24(8):2303-11.
Score: 0.037
-
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008 Feb; 51(2):339-44.
Score: 0.035
-
Ahmed A, Calhoun D. High blood pressure in older adults: a conversation with Dr David Calhoun. Am J Geriatr Cardiol. 2007 Nov-Dec; 16(6):391-2.
Score: 0.035
-
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
Score: 0.035
-
Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb; 131(2):453-9.
Score: 0.033
-
Nishizaka MK, Calhoun DA. Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens. 2006 Mar; 24(3):435-6.
Score: 0.031
-
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
Score: 0.027
-
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
Score: 0.025
-
Thomas SJ, Johnson DA, Guo N, Abdalla M, Booth JN, Spruill TM, Jackson CL, Yano Y, Sims M, Calhoun D, Muntner P, Redline S. Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens. 2020 10 21; 33(10):949-957.
Score: 0.022
-
Langford AT, Akinyelure OP, Moore TL, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN, Muntner P. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension. 2020 11; 76(5):1600-1607.
Score: 0.021
-
Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019 09; 37(9):1797-1804.
Score: 0.020
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Olmos LF, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. Hypertens Res. 2019 11; 42(11):1708-1715.
Score: 0.020
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Diaz Cambriles T, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Feced Olmos L, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019 06; 37(6):1269-1275.
Score: 0.020
-
Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S. Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation. 2019 03 05; 139(10):1275-1284.
Score: 0.019
-
Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019 02; 73(2):424-431.
Score: 0.019
-
Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med. 2018 12; 131(12):1463-1472.e7.
Score: 0.019
-
Parikh V, Thaler E, Kato M, Gillespie MB, Nguyen S, Withrow K, Calhoun D, Soose R, Stevens D, Stevens S, Larsen C, Reddy M, Lakkireddy D. Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apnea. Heart Rhythm. 2018 08; 15(8):1165-1170.
Score: 0.018
-
Irvin MR, Booth JN, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 03; 20(3):438-446.
Score: 0.018
-
Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 01 12; 31(2):133-135.
Score: 0.018
-
Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
Score: 0.017
-
Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil Womens Med. 1997 May-Jun; 42(3):198-205.
Score: 0.017
-
Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
Score: 0.017
-
Thomas SJ, Booth JN, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, Kidambi S, Shimbo D, Calhoun D, Muntner P. Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. J Am Soc Hypertens. 2017 Apr; 11(4):204-212.e5.
Score: 0.017
-
Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
Score: 0.017
-
Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
Score: 0.016
-
Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Respirology. 2016 11; 21(8):1486-1492.
Score: 0.016
-
Corr?a NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016 06; 10(6):510-516.e1.
Score: 0.016
-
Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. Am J Hypertens. 2016 Jan; 29(1):2-4.
Score: 0.015
-
Ellis AC, Patterson M, Dudenbostel T, Calhoun D, Gower B. Effects of 6-month supplementation with ?-hydroxy-?-methylbutyrate, glutamine and arginine on vascular endothelial function of older adults. Eur J Clin Nutr. 2016 Feb; 70(2):269-73.
Score: 0.015
-
Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
Score: 0.015
-
Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. Am J Med. 2015 Jul; 128(7):707-14.e2.
Score: 0.015
-
Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, Lloyd SG, Calhoun DA, Denney TS, Dell'italia LJ, Gupta H. Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson. 2014 Sep 26; 16:70.
Score: 0.014
-
Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
Score: 0.014
-
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
Score: 0.014
-
Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
Score: 0.014
-
White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
Score: 0.014
-
Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
Score: 0.014
-
Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
Score: 0.014
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
Score: 0.013
-
Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
Score: 0.013
-
Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013 Oct; 88(10):1099-107.
Score: 0.013
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
Score: 0.013
-
Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
Score: 0.013
-
Shimbo D, Levitan EB, Booth JN, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013 Feb; 31(2):370-6.
Score: 0.013
-
Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012 Oct; 14(10):694-700.
Score: 0.012
-
Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
Score: 0.012
-
Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S, Lloyd SG, Denney TS, Calhoun D, Dell'italia LJ, Gupta H. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging. 2012 Mar; 5(3):273-81.
Score: 0.012
-
Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
Score: 0.012
-
Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens. 2012 Jan-Feb; 6(1):66-72.
Score: 0.012
-
Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011 Aug; 29(8):1553-9.
Score: 0.011
-
Levine DA, Calhoun DA, Prineas RJ, Cushman M, Howard VJ, Howard G. Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens. 2011 Apr; 24(4):482-8.
Score: 0.011
-
Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011 Sep; 25(9):532-8.
Score: 0.011
-
Zappe DH, Palmer BF, Calhoun DA, Purkayastha D, Samuel R, Jamerson KA. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens. 2010 Jul; 24(7):483-91.
Score: 0.010
-
Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul; 23(7):479-89.
Score: 0.010
-
Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
Score: 0.009
-
White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
Score: 0.009
-
Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
Score: 0.009
-
Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005 Jun 15; 293(23):2884-91.
Score: 0.007
-
Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
Score: 0.007
-
Hicken BL, Calhoun DA, Barton JC, Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test. 2004; 8(2):90-7.
Score: 0.007
-
Aqel RA, Zoghbi GJ, Baldwin SA, Auda WS, Calhoun DA, Coffey CS, Perry GJ, Iskandrian AE. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens. 2003 Jun; 21(6):1157-62.
Score: 0.006
-
Payami H, Lee N, Zareparsi S, Gonzales McNeal M, Camicioli R, Bird TD, Sexton G, Gancher S, Kaye J, Calhoun D, Swanson PD, Nutt J. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology. 2001 May 22; 56(10):1363-70.
Score: 0.006